Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia

  • Lejla Vajzovic, MD, FASRS
  • Video
  • Published 2022

Related

    See more